Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samalizumab in Relapsing or Refractory B-CLL or Multiple Myeloma
NCT00648739Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2008
- Primary completion
- Dec 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of samalizumab in chronic lymphocytic leukemia (CLL), multiple myeloma (MM), sponsored by Alexion Pharmaceuticals. Started Jun 2008; status: terminated.
02
Drugs
samalizumab
03
Conditions
chronic lymphocytic leukemia (CLL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00648739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00648739.